<DOC>
	<DOCNO>NCT02810457</DOCNO>
	<brief_summary>The purpose research study compare effectiveness safety FKB238 AvastinÂ® men woman advanced/recurrent non squamous non-small cell lung cancer</brief_summary>
	<brief_title>Evaluation FKB238 Avastin Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients age 18 year old Newly diagnose advanced ( stage IV ) /recurrent nonsquamous NSCLC receive systemic anticancer therapy metastatic disease Histologically cytologically confirm diagnosis predominantly nonsquamous NSCLC Existence least 1 measurable lesion RECIST v1.1 Adequate hematological , renal liver function Eastern Collaborative Oncology Group Performance Status ( ECOG PS ) 0 1 Life expectancy longer 6 month Small cell lung cancer ( SCLC ) combination SCLC NSCLC . Squamouscell tumor mix adenosquamous carcinoma predominantly squamous nature Any unresolved toxicity prior systemic therapy Known sensitize EGFR mutation EML4ALK translocation positive mutation Previous dose vascular endothelial growth factor ( VEGF ) inhibitor Known hypersensitivity excipients Investigational Products ( IPs ) combination chemotherapy Use prohibit concomitant medication Known Hepatitis B , Hepatitis C , human immunodeficiency virus ( HIV ) infection Fertile men woman childbearing potential use adequate contraception . Other inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>